Dr. Dirk-Jan Opstelten

Dr. Dirk-Jan Opstelten

We are honored to introduce Dr. Opstelten, the Chairman of our Scientific Advisory Board. With a PhD in virology and over thirty years of experience in the pharmaceutical and biotechnology industries, Dr. Opstelten brings a wealth of knowledge and expertise to our team.

As Chairman, he actively participates in board meetings, offering invaluable advice on our programs and providing strategic leadership to achieve our objectives.

Dr. Opstelten has its own consultancy firm supporting biotech and pharmaceutical companies with medicinal product development and (interim) management of R&D organizations. In addition, he is board member of Desentum, a biotech company involved in the development of innovative vaccines for allergy. Previously, he has served in various pivotal roles, including Chief Scientific Officer at HAL Allergy Group and Program Director at Crucell (now J&J). His extensive background in leading R&D programs from early stage to market authorization and his contributions to scientific publications and patents underscore his commitment to advancing life sciences. We are privileged to have Dr. Opstelten guide our scientific endeavors.

Dr. Opstelten: “Batavia’s commitment to move the field of vaccines and virotherapy forward, with a string focus on science and quality is unsurpassed. I am delighted to chair the scientific advisory board with seasoned experts in this arena to support their mission.”

Dr. Dirk-Jan Opstelten - Chairman Scientific Advisory Board Batavia Biosciences

Dr. Keith Wells

Dr. Keith Wells

With more than 35 years of experience, Keith has been involved in the development of more than 90 clinical stage and licensed vaccines and biopharmaceutical products. His invaluable knowledge strengthens Batavia Biosciences’ groundbreaking vaccine projects.

Dr. Wells has been involved in the battle against measles, mumps, rubella, varicella, rotavirus, vaccinia, encephalitis viruses, Zika virus, and seasonal and pandemic influenza. Recently, he advised the Biomedical Advanced Research and Development Authority (BARDA) on the advanced development, licensure, acquisition, and manufacturing scale-up of medical countermeasures.

Keith’s extensive experience across the biopharmaceutical industry and government organizations for the development of vaccines for emerging diseases will further power our vision to reduce human suffering from infectious diseases, cancer and rare diseases.

Dr. Wells: “I’m delighted to be a part of the Batavia Biosciences Scientific Advisory Board as they continue to develop and employ cutting edge technologies to produce vital vaccines and biopharmaceutical products to improve global health.”

Dr. Keith Wells - Scientific Advisory Board Batavia Biosciences

Dr. Kutub Mahmood

Dr. Kutub Mahmood

As a seasoned leader with over 30 years of expertise in vaccine development, Dr. Mahmood brings industry and Global Health experience to Batavia Biosciences’ Scientific Advisory Board.

Kutub Mahmood, PhD, is currently working as PATH’s Scientific Director at the Center for Vaccines Innovation and Access (CVIA). He leads projects for polio vaccine development and scale-up for OPV, Sabin IPV (sIPV) and hexavalent vaccines. His other projects include work related to measles-rubella, influenza, RSV, Yellow fever, live rotavirus, and SARS-CoV2 with technologies including whole virion, inactivated, vectored, live attenuated, VLPs and subunit vaccines.

With Dr. Mahmood’s in-depth expertise, Batavia Biosciences strengthens its position as a frontrunner in vaccine development. With years of collaboration and research, Dr. Kutub Mahmood has developed an extensive global network that will be crucial in forming new partnerships and opportunities for Batavia Biosciences. This relationship enhances the company’s vaccine projects, leveraging Dr. Mahmood’s extensive experience and valuable insights.

Dr. Mahmood: “I have been continually impressed with Batavia’s deep scientific expertise in product development and contract manufacturing, which is at the core of its CDMO business in harnessing new low cost technologies for effective use in low and middle income countries. In the scientific advisory capacity, I have seen Batavia grown to expand in emerging diseases threat of pandemic potential and it will continue to play a pivotal role in new vaccines and biologicals development, contract development, manufacturing and technology transfer.

Kutub Mahmood

Dr. Guangping Gao

Dr. Guangping Gao

Dr. Gao’s illustrious career and groundbreaking work in AAV research positions him uniquely to guide and provide invaluable insights to Batavia Biosciences’ expanding portfolio in AAV-related projects.

Bringing Dr. Gao into our team is a testament to our commitment to harnessing top-tier expertise and ensuring that our AAV ventures are innovative and scientifically sound.

With Dr. Gao’s in-depth expertise, Batavia Biosciences strengthens its position as a frontrunner in cell and gene therapy. His extensive global network, built over years of collaboration and research, will be instrumental in forging new partnerships and opportunities for Batavia Biosciences. The relationship accelerates the company’s AAV-related projects while benefiting from Dr. Gao’s vast experience and insights.

Dr. Gao: “I am impressed with the extensive viral vaccine history of Batavia and their rapid development towards CGT viral vector programs.”

Menu Mobile

Copyright © 2023. All rights reserved.
Batavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16 2333 CL Leiden, The Netherlands

Reg No: 27362965, Registered in The Netherlands

Privacy Notice      |      Website Terms      |       Manage Preferences

Low-cost viral vector manufacturing

High-throughput screening for viral vectors

Viral vector manufacturing

Maximizing protein expression